Ralpancizumab Explained

Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2] [3]

This drug was developed by Pfizer.

Notes and References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 . WHO Drug Information . 27 . 4 . 2013 .
  2. Web site: Ralpancizumab . Statement On A Nonproprietary Name Adopted By The USAN Council . . .
  3. Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD . A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy . Clinical and Translational Science . 10 . 1 . 3–11 . January 2017 . 27860267 . 5351011 . 10.1111/cts.12430 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ralpancizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.